Biomédicaments « cibles » dans les maladies auto-immunes et inflammatoires systémiques

Flora Sagez(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Aurélien Guffroy(Hôpitaux Universitaires de Strasbourg), Rose‐Marie Javier(Laboratoire National de Référence), Christelle Sordet, Emmanuel Chatelus(Laboratoire National de Référence), Auriane Mallick(Hopitaux Civils de Colmar), Jacques‐Eric Gottenberg(Centre National de la Recherche Scientifique), N Rahal
Médecine thérapeutique
September 1, 2016
10.1684/met.2016.0597
Cited by 0

Related Papers

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
|Blood|1997|346
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207